GlassScriptPhysician profile
Christine Hickey
NPI 1063968113
$4,045.55
in general payments reported to CMS, 2019-2025
29 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $713 · 2023: $1,565 · 2024: $728 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,333.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $454.63 | 2022-2024 | Epclusa |
| Abbvie INC. | $429.03 | 2022-2024 | |
| Novo Nordisk INC | $386.59 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $272.68 | 2023-2025 | Repatha, Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $263.43 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Pfizer INC. | $247.49 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.97 | 2022-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $201.92 | 2022-2024 | |
| Viiv Healthcare Company | $169.86 | 2022-2025 | Apretude, Dovato |
| Merck Sharp & Dohme LLC | $168.06 | 2022-2024 | Pifeltro, Delstrigo, Dificid |
| Astrazeneca Pharmaceuticals LP | $167.41 | 2022-2025 | Breztri |
| Idorsia Pharmaceuticals US INC | $141.22 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $137.96 | 2025 | Fanapt |
| Glaxosmithkline, LLC. | $133.59 | 2023-2025 | Nucala, Arexvy, Shingrix |
| Abbott Laboratories | $127.85 | 2025 | Eterna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $93.45 | 2023-2025 | Injectafer |
| Lilly USA, LLC | $90.62 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Exact Sciences Corporation | $49.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medtronic, INC. | $32.74 | 2023 | Venaseal |
| Otsuka America Pharmaceutical, INC. | $29.30 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $27.90 | 2025 | |
| Braeburn INC. | $25.15 | 2025 | Brixadi |
| Viatris Specialty LLC | $23.84 | 2025 | Yupelri |
| Indivior INC. | $22.29 | 2025 | Sublocade |
| Biohaven Pharmaceutical Holding Company LTD. | $21.76 | 2022 | |
| Theratechnologies INC. | $21.71 | 2023 | Trogarzo, Egrifta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.89 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $20.19 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Hickey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.